Results 151 to 160 of about 23,157 (220)

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Lancet, The, 2020
Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment.
Moupali Das, Kenneth Mayer, Robert Grant   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority t

The Lancet HIV, 2023
BACKGROUND Cabotegravir plus rilpivirine is the only approved complete long-acting regimen for the maintenance of HIV-1 virological suppression dosed every 2 months.
M. Ramgopal, A. Castagna, C. Cazanave, V. Diaz-Brito, R. Dretler, S. Oka, O. Osiyemi, S. Walmsley, James Sims, G. di Perri, K. Sutton, Denise Sutherland-Phillips, Alessandro Berni, Christine Latham, Feifan Zhang, R. D'Amico, Miguel Pascual Bernáldez, R. Van Solingen-Ristea, V. Van Eygen, P. Patel, Vasiliki Chounta, W. Spreen, Harmony P. Garges, Kimberly Smith, J. van Wyk   +24 more
semanticscholar   +1 more source

Emtricitabine

2020
Emtricitabine (Emtriva, FTC) is an antiviral medicine which decreases the body's amount of HIV. Emtricitabine on of Anti-HIV drugs slow down or protect the immune system against damage and reduce the risk of diseases related to developing of AIDS. Emtricitabine use also for treatment of hepatitis B virus.
Abdulrahman A, Al-Majed, Ahmed H H, Bakheit, Bakr Mohammed, Al-Qahtani, Hamad M, Al-Kahtani, Ali S, Abdelhameed   +4 more
openaire   +3 more sources

Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.

The Lancet HIV, 2022
BACKGROUND There are few data available regarding the use of on-demand pre-exposure prophylaxis (PrEP) for HIV prevention. We aimed to assess PrEP effectiveness, adherence, and safety in adults using daily or on-demand PrEP.
J. Molina, J. Ghosn, L. Assoumou, C. Delaugerre, M. Algarte-Genin, G. Pialoux, C. Katlama, L. Slama, G. Liegeon, L. Béniguel, M. Ohayon, Hanane Mouhim, L. Goldwirt, B. Spire, B. Loze, L. Surgers, J. Pavie, J. Lourenço, Mohamed Ben-Mechlia, S. Le Mestre, D. Rojas‐castro, D. Costagliola   +21 more
semanticscholar   +1 more source

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.

The Lancet HIV, 2023
BACKGROUND For most adults with HIV-1 and hepatitis B virus (HBV) coinfection, initial recommended treatment is a tenofovir-containing antiretroviral regimen, but no randomised studies have compared tenofovir disoproxil fumarate with tenofovir ...
A. Avihingsanon, Hongzhou Lu, C. L. Leong, C. Hung, E. Koenig, S. Kiertiburanakul, M. Lee, K. Supparatpinyo, Fu-Guang Zhang, Sophia Rahman, M. D’Antoni, Hongyuan Wang, J. Hindman, Hal Martin, J. Baeten, Taisheng Li   +15 more
semanticscholar   +1 more source

Analytical RP-HPLC method development and validation for simultaneous estimation of Emtricitabine, Tenofovir and Bictegravir

Research Journal of Pharmacy and Technology, 2023
The Emtricitabine, Bictegravir and Tenofovir are used to treat Cystic fibrosis treatment. For estimation of this drug in bulk and pharmaceutical dosage form the standard, simple, accurate RP-HPLC method was devoloped, to run the sample column used was ...
A. Reddy, R. Devicharan, T. Rao
semanticscholar   +1 more source

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

The Lancet HIV, 2020
BACKGROUND ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz combined with ...
W. Venter, S. Sokhela, Bryony Simmons, Michelle A. Moorhouse, L. Fairlie, Nkuli Mashabane, Celicia M. Serenata, Godspower Akpomiemie, Masebole Masenya, A. Qavi, N. Chandiwana, K. McCann, Shane Norris, M. Chersich, G. Maartens, S. Lalla-Edward, A. Vos, P. Clayden, E. Abrams, Natasha Arulappan, A. Hill   +20 more
semanticscholar   +1 more source